Clinical development of the GnRH agonist leuprolide acetate depot
Leuprolide acetate is the first GnRH agonist that entered clinical development after the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been successively developed for various suppressive trea...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-06-01
|
| Series: | F&S Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666334122001222 |
| _version_ | 1797829102500052992 |
|---|---|
| author | Kristof Chwalisz, M.D., Ph.D. |
| author_facet | Kristof Chwalisz, M.D., Ph.D. |
| author_sort | Kristof Chwalisz, M.D., Ph.D. |
| collection | DOAJ |
| description | Leuprolide acetate is the first GnRH agonist that entered clinical development after the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been successively developed for various suppressive treatments in men, women, and children, which are available in the United States and globally. This mini review aims to summarize the key clinical studies that led to regulatory approval of leuprolide acetate depot suspension for injection. |
| first_indexed | 2024-04-09T13:15:05Z |
| format | Article |
| id | doaj.art-d7d62ce674c943f8b7b81c9f9dc295c6 |
| institution | Directory Open Access Journal |
| issn | 2666-3341 |
| language | English |
| last_indexed | 2024-04-09T13:15:05Z |
| publishDate | 2023-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | F&S Reports |
| spelling | doaj.art-d7d62ce674c943f8b7b81c9f9dc295c62023-05-12T04:17:13ZengElsevierF&S Reports2666-33412023-06-01423339Clinical development of the GnRH agonist leuprolide acetate depotKristof Chwalisz, M.D., Ph.D.0Reprint requests: Kristof Chwalisz, M.D., Ph.D., 4450 Rockwood Dr, Palm Harbor, Florida 34685.; Department of Obstetrics, Gynecology and Reproductive Biology, Michigan State University, East Lansing, MichiganLeuprolide acetate is the first GnRH agonist that entered clinical development after the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been successively developed for various suppressive treatments in men, women, and children, which are available in the United States and globally. This mini review aims to summarize the key clinical studies that led to regulatory approval of leuprolide acetate depot suspension for injection.http://www.sciencedirect.com/science/article/pii/S2666334122001222 |
| spellingShingle | Kristof Chwalisz, M.D., Ph.D. Clinical development of the GnRH agonist leuprolide acetate depot F&S Reports |
| title | Clinical development of the GnRH agonist leuprolide acetate depot |
| title_full | Clinical development of the GnRH agonist leuprolide acetate depot |
| title_fullStr | Clinical development of the GnRH agonist leuprolide acetate depot |
| title_full_unstemmed | Clinical development of the GnRH agonist leuprolide acetate depot |
| title_short | Clinical development of the GnRH agonist leuprolide acetate depot |
| title_sort | clinical development of the gnrh agonist leuprolide acetate depot |
| url | http://www.sciencedirect.com/science/article/pii/S2666334122001222 |
| work_keys_str_mv | AT kristofchwaliszmdphd clinicaldevelopmentofthegnrhagonistleuprolideacetatedepot |